{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Small+Cell+Carcinoma&page=23", "query": { "condition": "Cervical Small Cell Carcinoma", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 560, "total_pages": 56, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Small+Cell+Carcinoma&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Small+Cell+Carcinoma&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T05:39:42.474Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03195699", "title": "Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Non Small Cell Lung Cancer", "Hepatocellular Cancer", "Colorectal Cancer", "Gastric Adenocarcinoma", "Melanoma", "Advanced Cancer" ], "interventions": [ { "name": "TTI-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tvardi Therapeutics, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 64, "start_date": "2017-11-15", "completion_date": "2024-06-24", "has_results": false, "last_update_posted_date": "2025-03-21", "last_synced_at": "2026-10-16T05:39:42.474Z", "location_count": 2, "location_summary": "Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03195699" }, { "nct_id": "NCT01212627", "title": "Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Ridaforolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Angela Taber MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2010-09", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2021-02-16", "last_synced_at": "2026-10-16T05:39:42.474Z", "location_count": 2, "location_summary": "Pawtucket, Rhode Island • Providence, Rhode Island", "locations": [ { "city": "Pawtucket", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01212627" }, { "nct_id": "NCT00620295", "title": "Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Kidney Cancer", "Lung Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Sarcoma" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 17, "start_date": "2007-03", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-10-16T05:39:42.474Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00620295" }, { "nct_id": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Astrocytoma, IDH-Mutant", "Glioblastoma, IDH-wildtype", "Brain Metastases, Adult", "Cervical Cancer", "Colorectal Cancer", "Esophageal Cancer", "Esophageal Squamous Cell Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Head and Neck Squamous Cell Carcinoma", "Melanoma", "Merkel Cell Carcinoma", "Microsatellite Instability-High Solid Malignant Tumor", "Mismatch Repair Deficient Solid Malignant Tumor", "Microsatellite Instability-High Colorectal Cancer", "Mismatch Repair Deficient Colorectal Cancer", "Non-small Cell Lung Cancer", "Renal Cell Carcinoma", "Small Cell Lung Cancer", "Squamous Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "NEO212 Oral Capsule", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "FOLFIRI Protocol", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neonc Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2023-11-01", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-16T05:39:42.474Z", "location_count": 8, "location_summary": "Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06047379" }, { "nct_id": "NCT06400472", "title": "A Study of Sofe-M in Participants With Selected Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Neoplasms", "Endometrial Neoplasms", "Uterine Cervical Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Triple Negative Breast Neoplasms", "Pancreatic Neoplasm", "Colorectal Neoplasms" ], "interventions": [ { "name": "Sofe-M", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 575, "start_date": "2024-05-20", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-16T05:39:42.474Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06400472" }, { "nct_id": "NCT07807345", "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head & Neck Squamous Cell Carcinoma", "Non-Small Cell Lung Cancer", "Esophageal Cancer", "Gastric Cancer", "Colorectal Cancer", "Endometrial Cancer", "Urothelial Carcinoma (UC)", "Breast Cancer" ], "interventions": [ { "name": "STRO-006", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sutro Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2026-09-14", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-16T05:39:42.474Z", "location_count": 7, "location_summary": "La Jolla, California • Orlando, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07807345" }, { "nct_id": "NCT00836992", "title": "Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anal Cancer", "Colorectal Cancer", "Esophageal Cancer", "Extrahepatic Bile Duct Cancer", "Gallbladder Cancer", "Gastric Cancer", "Head and Neck Cancer", "Liver Cancer", "Lung Cancer", "Pancreatic Cancer", "Small Intestine Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 144, "start_date": "2009-01", "completion_date": "2015-07-27", "has_results": false, "last_update_posted_date": "2017-05-24", "last_synced_at": "2026-10-16T05:39:42.474Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00836992" }, { "nct_id": "NCT05538572", "title": "A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Glioblastoma", "Head and Neck Squamous Cell Carcinoma", "Malignant Mesothelioma", "Non-small Cell Lung Cancers", "Sarcoma", "Endometrial Cancer" ], "interventions": [ { "name": "PRT3645", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-12-27", "completion_date": "2024-06-26", "has_results": false, "last_update_posted_date": "2024-07-01", "last_synced_at": "2026-10-16T05:39:42.474Z", "location_count": 12, "location_summary": "New Haven, Connecticut • Celebration, Florida • Miami, Florida + 8 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Celebration", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05538572" }, { "nct_id": "NCT00264472", "title": "A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "ADH300004", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adherex Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2006-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-12-15", "last_synced_at": "2026-10-16T05:39:42.474Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00264472" }, { "nct_id": "NCT05412875", "title": "Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Lung Non-Small Cell Carcinoma", "Stage I Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage I Lung Cancer AJCC v8", "Stage IA1 Lung Cancer AJCC v8", "Stage IA2 Lung Cancer AJCC v8", "Stage IA3 Lung Cancer AJCC v8", "Stage IB Lung Cancer AJCC v8", "Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage II Lung Cancer AJCC v8", "Stage IIA Lung Cancer AJCC v8", "Stage IIB Lung Cancer AJCC v8", "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Nicotine Replacement", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 0, "start_date": "2024-01-01", "completion_date": "2024-01-31", "has_results": false, "last_update_posted_date": "2024-04-12", "last_synced_at": "2026-10-16T05:39:42.474Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05412875" } ] }